Healthy Q2 and H1; resulting in consecutive guidance upgrade
04/08/22 -"DiaSorin released healthy Q2 results. While, as expected, non-COVID-19 offerings continued to do well, slower-than-expected moderation in COVID-19 testing sales was a pleasant surprise – also ..."
Pages
63
Language
English
Published on
04/08/22
You may also be interested by these reports :
20/02/26
Since we began coverage on Elekta (BUY; Sweden) in January 2020, medical equipment and software provider for cancer treatment using radiation ...
18/02/26
Emeis delivered a robust operational recovery in 2025, characterised by EBITDAR growth that exceeded management guidance and a further strengthened ...
16/02/26
The target price benefits from higher earnings expectations, along with a 20% premium added to the peer-based valuation. This reflects the firm’s ...
13/02/26
Dominant positioning for critical medical equipment (such as ventilators and heart-lung machines) in hospitals’ operating rooms, with two-thirds ...